top of page
Medical Checkup

NIMBLE

Trial Enrolment Status

CLOSED

Disease Under Study

ASTHMA

Duration

52 Weeks

About the Trial

Utilization of Depemokimab Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Mechanism of Action:

​

Duration of Study

52 Weeks

Phase

​

Principal Investigator

Dr. George Philteos

Sub-Investigator

Dr. Anushya Chelvanathan

Study Coordinator

Nusrat Jahan

Dr. Philteos and Associates | Dynamic Drug Advancement Limited

Address:

Hours:

601 Harwood Avenue South, Suite 201

Ajax, Ontario L1S 2J5

M-F:

9:00am - 5:00pm

Closed on statutory holidays

Main Office Phone: 

 

 

Main Office Fax:   

Clinical Trial Phone:

Clinical Trial Fax: 

Dr. Philteos: (905) 427-1419

Dr. Chelvanathan: (905) 239 0225

Dr. O'Loghlen: (905) 239 0221

(905) 427-0346

(365) 885-9086

(905) 239-2399

©2022 by Dynamic Drug Advancement. Proudly created with Wix.com

bottom of page